Peptide Database

Peptide NameIPB06(SARS-CoV-2-S (1183-1205))

Function Ontology

Antimicrobial

Antiviral

Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV

Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2

Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition

Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor

Standard StatusStandard

Sequence Length23 amino acids

Chemical FormulaC113H194N32O39

DescriptionStandard

        IDRLNEVAKNLNESLIDLQELGK
    

Molecular Weight2624.94 Da

Isoelectric Point (pI)4.51

Net Charge (pH 7.0)-2.23

Net Charge (pH 7.4) -2.44

Charge Density (pH 7.0) -0.0970

GRAVY Index-0.48

Hydrophobic Moment 0.69

Boman Index-0.12

Instability Index33.52

Aliphatic Index 135.65

Aromaticity 0.0000

Extinction Coeff. Reduced 0.00

Extinction Coeff. Oxidized 0.00

The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.

Amino Acid Composition

TPSA 1196.55

LogP -11.36

H-bond Donors 39.0

H-bond Acceptors 37.0

Rotatable Bonds 95.0

Heavy Atoms 184.0

Ring Count 0.0

Amide Bonds 26.0

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.

2D CHEMICAL STRUCTURE

Drag to move

Drag to move. Use the buttons to zoom.

RECORD: Rec_0021626 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

FamilyHR2 fusion-inhibitory peptide

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitynoncanonically modified peptide (cholesterol conjugate) [Modified]

N-TermNone

C-TermChol

Other ModsLys side-chain cholesterol conjugation

Bio-Activity Profile

Function

Antiviral Anti-SARS-CoV-2 Fusion inhibition

TargetSARS-CoV-2; 293T/ACE2 cells

Activity>5 μM

MethodCell-cell fusion inhibition (IC50)

Half-LifeMammalian: 20 h; Yeast: 30 min; E. coli: >10 h

PaperDesign of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. | Zhu Y, Yu D, Yan H, Chong H, He Y. | J Virol. 2020 Jul 1;94(14):e00635-20. | DOI:10.1128/JVI.00635-20 | PMID:32376627 PMID32376627 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32376627/

RECORD: Rec_0121775 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

FamilyHR2 fusion-inhibitory peptide

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitynoncanonically modified peptide (cholesterol conjugate) [Modified]

N-TermNone

C-TermChol

Other ModsLys side-chain cholesterol conjugation

Bio-Activity Profile

Function

Antiviral Anti-SARS-CoV Fusion inhibition

TargetSARS-CoV; 293T/ACE2 cells

Activity>25 μM

MethodPseudovirus infection inhibition (IC)

Half-LifeMammalian: 20 h; Yeast: 30 min; E. coli: >10 h

PaperDesign of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. | Zhu Y, Yu D, Yan H, Chong H, He Y. | J Virol. 2020 Jul 1;94(14):e00635-20. | DOI:10.1128/JVI.00635-20 | PMID:32376627 PMID32376627 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32376627/

RECORD: Rec_0138496 VERIFIED: NO

Provenance & Taxonomy

OrganismSevere acute respiratory syndrome coronavirus 2 [Virus]

FamilyHR2-derived fusion inhibitor

Tax ID2697049

Structure & Mods

Configlinear peptide [Linear]

Chiralitynoncanonically modified peptide (cholesterol conjugate) [Modified]

Other ModsLys side-chain cholesterol conjugation

Bio-Activity Profile

Function

Antiviral

TargetSevere acute respiratory syndrome coronavirus 2

Activity- -

Method-

RECORD: Rec_0161062 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

FamilyHR2 fusion-inhibitory peptide

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitynoncanonically modified peptide (cholesterol conjugate) [Modified]

N-TermNone

C-TermChol

Other ModsLys side-chain cholesterol conjugation

Bio-Activity Profile

Function

Antiviral Anti-SARS-CoV-2 Fusion inhibition

TargetSARS-CoV-2; 293T/ACE2 cells

Activity>25 μM

MethodPseudovirus infection inhibition (IC50)

Half-LifeMammalian: 20 h; Yeast: 30 min; E. coli: >10 h

PaperDesign of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. | Zhu Y, Yu D, Yan H, Chong H, He Y. | J Virol. 2020 Jul 1;94(14):e00635-20. | DOI:10.1128/JVI.00635-20 | PMID:32376627 PMID32376627 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32376627/

RECORD: Rec_0244709 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

FamilyHR2 fusion-inhibitory peptide

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitynoncanonically modified peptide (cholesterol conjugate) [Modified]

N-TermNone

C-TermChol

Other ModsLys side-chain cholesterol conjugation

Bio-Activity Profile

Function

Antiviral Anti-VSV Fusion inhibition

TargetVesicular stomatitis virus pseudovirus; 293T/ACE2 cells

Activity>50 μM

MethodPseudovirus infection inhibition (IC50)

Half-LifeMammalian: 20 h; Yeast: 30 min; E. coli: >10 h

PaperDesign of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. | Zhu Y, Yu D, Yan H, Chong H, He Y. | J Virol. 2020 Jul 1;94(14):e00635-20. | DOI:10.1128/JVI.00635-20 | PMID:32376627 PMID32376627 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32376627/

1 2 NEXT LAST

Showing 5 records · Page 1 of 2